About: Clinical Guidance for the Management of Patients with Urothelial Cancers During the COVID-19 Pandemic

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clinical Guidance for the Management of Patients with Urothelial Cancers During the COVID-19 Pandemic – Rapid Review Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Clinical Guidance for the Management of Patients with Urothelial Cancers During the COVID-19 Pandemic – Rapid Review
Creator	Choudhury, Ananya Birtle, Alison Hoskin, Peter Huddart, Robert James, Nicholas Patel, Patel, Karan Varughese, Mohini
Source	Elsevier; Medline; PMC
abstract	Abstract The current COVID-19 pandemic presents a substantial obstacle to cancer patient care. Data from China as well as risk models suppose that cancer patients, particularly those on active, immunosuppressive therapies are at higher risks of severe infection from the illness. In addition, staff illness and restructuring of services to deal with the crisis will inevitably place treatment capacities under significant strain. These guidelines aim to expand on those provided by NHS England regarding cancer care during the coronavirus pandemic by examining the known literature and provide guidance in managing patients with urothelial and rarer urinary tract cancers. In particular, they address the estimated risk and benefits of standard treatments and consider the alternatives in the current situation. As a result, it is recommended that this guidance will help form a framework for shared decision making with patients. Moreover, they do not advise a one-size-fits-all approach but recommend continual assessment of the situation with discussion within and between centres.
has issue date	2020-04-24(xsd:dateTime)
bibo:doi	10.1016/j.clon.2020.04.005
bibo:pmid	32389318
has license	els-covid
sha1sum (hex)	1fb662f382f5c37b249657e3d71c1bb89de4f1e1
schema:url	https://doi.org/10.1016/j.clon.2020.04.005
resource representing a document's title	Clinical Guidance for the Management of Patients with Urothelial Cancers During the COVID-19 Pandemic – Rapid Review
has PubMed Central identifier	PMC7180390
has PubMed identifier	32389318
schema:publication	Clin Oncol (R Coll Radiol)
resource representing a document's body	covid:1fb662f382f5c37b249657e3d71c1bb89de4f1e1#body_text
is schema:about of	named entity 'NHS England' named entity 'care' named entity 'Cancers' named entity 'Cancers' named entity 'Management' named entity 'cancer' named entity 'illness' named entity 'managing' named entity 'active' named entity 'urothelial' named entity 'infection' named entity 'Cancers' named entity 'COVID-19 Pandemic' named entity 'Title page' named entity 'COVID-19 Pandemic' named entity 'COVID-19 pandemic' named entity 'objective response rate' named entity 'distal' named entity 'PDL1' named entity 'COVID' named entity 'decision-making' named entity 'cisplatin' named entity 'China' named entity 'radiotherapy' named entity 'infection' named entity 'COVID-19 pandemic' named entity 'neoadjuvant chemotherapy' named entity '12 weeks' named entity 'vinblastine' named entity 'Neoadjuvant chemotherapy' named entity 'pneumonitis' named entity 'methotrexate' named entity 'adjuvant' named entity 'meta-analysis' named entity 'immunosuppression' named entity 'bladder cancer' named entity 'meta-analysis' named entity 'non-significant' named entity 'chemotherapy' named entity 'prognosis' named entity 'risk of death' named entity 'Studies examining' named entity 'bladder cancer' named entity 'chemotherapy' named entity 'bladder cancer' named entity 'risk factors' named entity 'adjuvant chemotherapy' named entity 'metastatic disease' named entity 'toxicity' named entity 'disease-free survival' named entity 'chemotherapy' named entity 'bladder cancer' named entity 'neoadjuvant chemotherapy' named entity '5-fluorouracil' named entity 'gemcitabine' named entity 'Severe acute respiratory syndrome coronavirus 2' named entity 'NICE' named entity 'tumour' named entity 'growth factors' named entity 'cancer care' named entity 'COVID' named entity 'cancer care' named entity 'patient safety' named entity 'patient care' named entity 'gemcitabine' named entity 'mortality risk' named entity 'follow-up' named entity 'radiotherapy' named entity 'systemic therapy' named entity 'pathologies' named entity 'radiotherapy' named entity 'cystectomy' named entity 'neoadjuvant chemotherapy' named entity 'disease-free survival'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software